Imugene
Sydney, New South Wales, Australia · Biotechnology, Health Care, Medical
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour res
Key facts
- Headquarters
- Sydney, New South Wales, Australia
- Employees
- 23
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- www.imugene.com
- Company page
Recent activity at Imugene
- : Imugene Limited Announces Resignation of CEO Leslie Chong Effective Immediately
- : Imugene Appoints Darren Keamy as Chief Financial Officer and Company Secretary
- : Imugene appoints Dr John Byon as senior vice president of clinical development
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Leslie Chong, Chief Executive Officer
- Darren Keamy, Chief Financial Officer
- John Byon, Senior Vice President of Clinical Development
Verified email and direct lines for Imugene’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Imugene in the news
- Imugene Reports New Responses With Azercabtagene Zapreleucel Plus BTK Inhibitor in Phase 1b Blood Cancer Trial - Oncodaily (Oct 05, 2026)
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL - PR Newswire (Jul 14, 2025)
- Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Applied Clinical Trials Online (Jul 16, 2025)
- Imugene Limited (IMU.AX) stock price, news, quote and history - Yahoo Finance Australia (May 29, 2017)
- Inside Biotech: FDA fast-track nod sharpens focus on Imugene's off-the-shelf CAR T ambitions - Proactive Investors Australia (Jun 09, 2026)
- Imugene (ASX: IMU) up 155% this week - maybe this cancer-killing virus really works? - Dhaka Tribune (Nov 09, 2023)
- Imugene shares up 6pc on after ‘milestone’ for cancer vaccine - Stockhead (Apr 21, 2021)
- Imugene (ASX:IMU) - Stock Analysis - Simply Wall St (Dec 01, 2017)
Companies similar to Imugene
- OncoNano Medicine · Biotechnology, Health Care, Medical, Therapeutics
- NuCana · Biotechnology, Health Care, Medical, Therapeutics
- Aethlon Medical · Biotechnology, Health Care, Medical, Therapeutics
- Immunocine Cancer Center · Biotechnology, Health Care, Medical, Therapeutics
- Aerska · Biotechnology, Health Care, Medical, Therapeutics
About Imugene: questions and answers
What does Imugene do?
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour res
Where is Imugene headquartered?
Imugene is headquartered in Sydney, New South Wales, Australia.
How many employees does Imugene have?
Imugene has about 23 employees.
Who leads Imugene?
Leslie Chong is a Chief Executive Officer at Imugene.
What is the latest news on Imugene?
On Jul 27, 2026, Imugene Limited Announces Resignation of CEO Leslie Chong Effective Immediately
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy